Skip to main content

Adaptimmune Therapeutics Stock Forecast, Price & News

+0.26 (+5.70 %)
(As of 05/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume424,859 shs
Average Volume953,022 shs
Market Capitalization$749.37 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADAP News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Adaptimmune Therapeutics logo

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ADAP
Year FoundedN/A

Sales & Book Value

Annual Sales$1.12 million
Book Value$1.18 per share


Net Income$-137,160,000.00
Net Margins-3,858.14%




Market Cap$749.37 million
Next Earnings Date8/5/2021 (Estimated)


Overall MarketRank

1.44 out of 5 stars

Medical Sector

652nd out of 2,044 stocks

Biological Products, Except Diagnostic Industry

88th out of 176 stocks

Analyst Opinion: 3.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions

Is Adaptimmune Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Adaptimmune Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADAP, but not buy additional shares or sell existing shares.
View analyst ratings for Adaptimmune Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Adaptimmune Therapeutics?

Wall Street analysts have given Adaptimmune Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adaptimmune Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Adaptimmune Therapeutics?

Adaptimmune Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 3,840,000 shares, an increase of 27.2% from the March 31st total of 3,020,000 shares. Based on an average trading volume of 877,500 shares, the short-interest ratio is currently 4.4 days.
View Adaptimmune Therapeutics' Short Interest

When is Adaptimmune Therapeutics' next earnings date?

Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Adaptimmune Therapeutics

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) announced its quarterly earnings results on Wednesday, May, 5th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.01. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 44.94% and a negative net margin of 3,858.14%.
View Adaptimmune Therapeutics' earnings history

How has Adaptimmune Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Adaptimmune Therapeutics' stock was trading at $2.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADAP stock has increased by 63.9% and is now trading at $4.82.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ADAP?

4 brokers have issued 1-year target prices for Adaptimmune Therapeutics' stock. Their forecasts range from $6.00 to $42.00. On average, they expect Adaptimmune Therapeutics' stock price to reach $19.00 in the next year. This suggests a possible upside of 294.2% from the stock's current price.
View analysts' price targets for Adaptimmune Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Adaptimmune Therapeutics' key executives?

Adaptimmune Therapeutics' management team includes the following people:
  • Mr. Adrian G. Rawcliffe, CEO, Principal Accounting Officer & Director (Age 49, Pay $720.86k)
  • Dr. Helen Katrina Tayton-Martin, Co-Founder & Chief Bus. Officer (Age 54, Pay $588.19k)
  • Mr. William C. Bertrand Jr., Chief Operating Officer (Age 56, Pay $602.61k)
  • Mr. Gavin Hilary James Wood BA (Hons), ACA, Chief Financial Officer (Age 51)
  • Mr. Sébastien Desprez, VP of Communications & Investor Relations
  • Ms. Margaret Henry, Head of PR & Company Sec.
  • Dr. Rafael G. Amado, Pres of R&D (Age 57)
  • Dr. Arundathy Nirmalini Pandite M.B.A., M.D., Sr. VP of Clinical Devel. (Age 62)
  • Trupti Trivedi, Head of Biometrics and VP
  • Prof. P. Julian Dyson Ph.D., Head of Autoimmune Group

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics CEO Adrian Rawcliffe on Adrian Rawcliffe has an approval rating of 100% among Adaptimmune Therapeutics' employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Adaptimmune Therapeutics' key competitors?

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (7.38%), JPMorgan Chase & Co. (1.08%), BlackRock Inc. (0.96%), Rafferty Asset Management LLC (0.66%), Healthcare of Ontario Pension Plan Trust Fund (0.29%) and SG Americas Securities LLC (0.15%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Elliot Norry, Gavin Wood, James Noble, John Lunger, Lawrence M Alleva, Peter W Sonsini, Rafael Amado and William C Bertrand, Jr.
View institutional ownership trends for Adaptimmune Therapeutics

Which major investors are selling Adaptimmune Therapeutics stock?

ADAP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, and WS Management Lllp. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Elliot Norry, James Noble, John Lunger, and William C Bertrand, Jr.
View insider buying and selling activity for Adaptimmune Therapeutics
or view top insider-selling stocks.

Which major investors are buying Adaptimmune Therapeutics stock?

ADAP stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Rafferty Asset Management LLC, JPMorgan Chase & Co., Healthcare of Ontario Pension Plan Trust Fund, SG Americas Securities LLC, QS Investors LLC, Henry James International Management Inc., and Trexquant Investment LP. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Gavin Wood, Lawrence M Alleva, Peter W Sonsini, and William C Bertrand, Jr.
View insider buying and selling activity for Adaptimmune Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $4.82.

How much money does Adaptimmune Therapeutics make?

Adaptimmune Therapeutics has a market capitalization of $749.37 million and generates $1.12 million in revenue each year. The biotechnology company earns $-137,160,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does Adaptimmune Therapeutics have?

Adaptimmune Therapeutics employs 462 workers across the globe.

What is Adaptimmune Therapeutics' official website?

The official website for Adaptimmune Therapeutics is

Where are Adaptimmune Therapeutics' headquarters?

Adaptimmune Therapeutics is headquartered at 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]

This page was last updated on 5/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.